Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Actelion Planning Tracleer Morbidity/Mortality Study In Idiopathic Pulmonary Fibrosis

This article was originally published in The Pink Sheet Daily

Executive Summary

BUILD studies fail to show effect of bosentan on primary endpoints of exercise improvement, but positive morbidity/mortality trends were seen in idiopathic pulmonary fibrosis patients.

You may also be interested in...

Tracleer “Dear Doctor” Letter Emphasizes Monthly Liver Monitoring

Reports of hepatotoxicity are included in boxed warning for Actelion’s pulmonary arterial hypertension therapy.

NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts